Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-finding study of AZD3355 added to PPI therapy in partial responders with GERD
2009-012935-13Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lesogaberan in gastroesophageal reflux disease (GERD) (5 arms), sponsored by AstraZeneca. Primary endpoint: Primary efficacy responder rate based on Overall symptoms domain in RESQ-eD. Started Sep 2009; status: completed.
02
Drugs
lesogaberan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2009-012935-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012935-13.